Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | pantothenate kinase subunit, putative | 0.0084 | 1 | 1 |
Toxoplasma gondii | fumble protein | 0.0084 | 1 | 1 |
Leishmania major | pantothenate kinase subunit, putative | 0.0084 | 1 | 1 |
Trichomonas vaginalis | pantothenate kinase, putative | 0.0084 | 1 | 1 |
Schistosoma mansoni | pantothenate kinase | 0.0084 | 1 | 1 |
Loa Loa (eye worm) | pantothenate kinase | 0.0084 | 1 | 1 |
Echinococcus granulosus | pantothenate kinase 4 | 0.0084 | 1 | 1 |
Onchocerca volvulus | Fumble homolog | 0.0084 | 1 | 0.5 |
Trichomonas vaginalis | pantothenate kinase, putative | 0.0084 | 1 | 1 |
Trichomonas vaginalis | pantothenate kinase, putative | 0.0084 | 1 | 1 |
Giardia lamblia | Pantothenate kinase 4 | 0.0084 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable isocitrate dehydrogenase [NADP] Icd1 (oxalosuccinate decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) | 0.0015 | 0 | 0.5 |
Entamoeba histolytica | pantothenate kinase 1, putative | 0.0084 | 1 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0035 | 0.2917 | 0.2917 |
Toxoplasma gondii | pantothenate kinase | 0.0035 | 0.2917 | 0.2917 |
Schistosoma mansoni | pantothenate kinase | 0.0084 | 1 | 1 |
Plasmodium falciparum | pantothenate kinase 1, putative | 0.0084 | 1 | 1 |
Trypanosoma brucei | pantothenate kinase subunit, putative | 0.0084 | 1 | 1 |
Echinococcus multilocularis | pantothenate kinase 4 | 0.0084 | 1 | 1 |
Plasmodium falciparum | pantothenate kinase 2, putative | 0.0035 | 0.2917 | 0.2917 |
Plasmodium vivax | pantothenate kinase, putative | 0.0084 | 1 | 1 |
Trichomonas vaginalis | pantothenate kinase, putative | 0.0084 | 1 | 1 |
Trypanosoma cruzi | pantothenate kinase subunit, putative | 0.0084 | 1 | 1 |
Trichomonas vaginalis | pantothenate kinase, putative | 0.0084 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.